TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02247856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer (VMN)
Description: Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
Study: NCT04163770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: caliberation of pacemaker
Description: evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: caliberation of pacemaker
Description: evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
Study: NCT02802085

Intervention type: DEVICE
Intervention: VEGA Knee
Description: TKA
Study: NCT03078517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway protector
Description: After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
Study: NCT02514070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil
Description: 4 gel capsules, 3 times/day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Description: 4 gel capsules, 3 times/day for 6 weeks
Study: NCT02046200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00041015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT02046200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Study: NCT00041015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT00153166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin and pioglitazone
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin and pioglitazone
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin and pioglitazone
Description: atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin/placebo
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily
Study: NCT00507507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC
Description: Emtricitabine (FTC) 200 mg capsule taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match FTC taken once daily
Study: NCT02326090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-UCA ophthalmic solution 1.0%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cis-UCA ophthalmic solution 2.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Study: NCT02560792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Condition
Description: Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Affect Condition
Description: Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Participants receive no information about affective response
Study: NCT00581789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib, sunitinib
Description: erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
Study: NCT03044288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
Study: NCT00449007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 6 months
Study: NCT00153166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin/placebo
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin/placebo
Description: atorvastatin 80 mg orally once daily and matching placebo orally twice daily
Study: NCT00449007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: 6 months
Study: NCT03387774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Study: NCT01169259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study: NCT03007589

Intervention type: DRUG
Group type: OTHER
Intervention: otc sunscreens
Description: Sunscreens of various SPF levels and ingredients

Intervention type: DRUG
Group type: OTHER
Intervention: otc sunscreens
Description: Sunscreens of various SPF levels and ingredients

Intervention type: OTHER
Group type: OTHER
Intervention: sun protection fabrics
Description: fabrics

Intervention type: OTHER
Group type: OTHER
Intervention: sun protection fabrics
Description: fabrics

Intervention type: OTHER
Group type: OTHER
Intervention: Optical Filters
Description: Optical band pass or long pass filters or surfaces/mirrors used in solar simulators

Intervention type: OTHER
Group type: OTHER
Intervention: Optical Filters
Description: Optical band pass or long pass filters or surfaces/mirrors used in solar simulators
Study: NCT00153166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone/placebo
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone/placebo
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/placebo
Description: pioglitazone 30 mg orally once daily and matching placebo orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo/placebo
Description: placebo orally three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo/placebo
Description: placebo orally three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/placebo
Description: placebo orally three times daily
Study: NCT01863862

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy or radiotherapy
Description: 50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision.
Study: NCT00041015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Study: NCT04179058

Intervention type: OTHER
Intervention: Follow-up
Description: Clinical data, radiological data and laboratory tests follow-up

Intervention type: OTHER
Intervention: Follow-up
Description: Clinical data, radiological data and laboratory tests follow-up
Study: NCT00319696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Description: Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Bosentan 125-mg oral tablets administered b.i.d. (target dose)
Study: NCT02275962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study: NCT04558450

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: carotid-femoral pulse-wave velocity
Description: early vascular aging tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: carotid-femoral pulse-wave velocity
Description: early vascular aging tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: carotid-femoral pulse-wave velocity
Description: early vascular aging tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: carotid-femoral pulse-wave velocity
Description: early vascular aging tests
Study: NCT00525213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rob 803
Description: two capsules per day during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rob 803
Description: two capsules per day during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rob 803
Description: two capsules per day during 12 weeks
Study: NCT03387774

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy.
Study: NCT01524458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-Oral Endoscopic Myotomy
Description: To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
Study: NCT00375310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Sorafenib
Description: Gemcitabine is given IV~Sorafenib is given orally of varying doses:~1. Sorafenib 200 mg po qd ( during combination therapy)~2. Sorafenib 400 mg po qd ( during combination therapy)~3. Sorafenib 400 mg po bid ( during combination therapy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy CTV daily for 5 weeks
Study: NCT02229292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.
Study: NCT01094483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 500 mg/esomeprazole 20 mg oral tablet
Study: NCT02229292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.
Study: NCT03488485

Intervention type: DRUG
Group type: OTHER
Intervention: Direct Acting Antivirals
Description: DAAs given in patients with viremic chronic hepatitis C
Study: NCT01094483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Asprin 81 mg enteric coated tablet
Study: NCT05357079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Topical application
Study: NCT01094483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA
Description: Asprin 81 mg enteric coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01224899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left cervico-thoracic sympathetic blockade
Description: Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
Study: NCT04760795

Intervention type: OTHER
Intervention: PTSD Check List (PCL) scale
Description: PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.

Intervention type: OTHER
Intervention: PTSD Check List (PCL) scale
Description: PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.

Intervention type: OTHER
Intervention: Brief COPE scale
Description: Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.

Intervention type: OTHER
Intervention: Brief COPE scale
Description: Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.

Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (during containment)
Description: GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.

Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (during containment)
Description: GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.

Intervention type: OTHER
Intervention: Analog scale
Description: Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.

Intervention type: OTHER
Intervention: Analog scale
Description: Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.

Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (post containment)
Description: GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.

Intervention type: OTHER
Intervention: GAD-7 (Generalized Anxiety Disorder) scale (post containment)
Description: GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.

Intervention type: OTHER
Intervention: Big Five Inventory (BFI) scale
Description: Big Five Inventory (BFI) will be realized to evaluated personality.

Intervention type: OTHER
Intervention: Big Five Inventory (BFI) scale
Description: Big Five Inventory (BFI) will be realized to evaluated personality.

Intervention type: OTHER
Intervention: Relationship Scales Questionnaire (RSQ)
Description: Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.

Intervention type: OTHER
Intervention: Relationship Scales Questionnaire (RSQ)
Description: Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
Study: NCT03156153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
Study: NCT02190591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Labor Ball
Description: Peanut Labor Ball
Study: NCT00525213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules per day during 12 weeks
Study: NCT02116595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high or low acid diet
Description: high or low acid diets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high or low acid diet
Description: high or low acid diets